Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Kataja, V ^a,c   Castiglione, M ^b  

^a VAASA CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; TRASTUZUMAB;

AGING; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; DOCTOR PATIENT RELATION; EARLY DIAGNOSIS; EUROPEAN UNION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOREACTIVITY; INCIDENCE; LYMPH NODE BIOPSY; MAMMOGRAPHY; MASTECTOMY; MORTALITY; OVARY FUNCTION; PALPATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; SENTINEL LYMPH NODE BIOPSY; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT;

BREAST NEOPLASMS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; RISK FACTORS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549090114     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp114     Document Type: Article

References (18)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553.
3. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
4. Hughes L, Wong M, Page D et al. Five year results of Intergroup study E5194: Local excision alone (without radiation treatment) for selected patients with ductal carcinoma in situ (DCIS). San Antonio Breast Cancer Symposium; 2006 Abstr 29.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
6. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
7. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
8. Jakesz R, Kaufmann M, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and the ARNO 95 trial. Lancet 2005; 366: 455-462.
9. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092 [erratum, N Engl J Med 2004; 351: 2641].
10. Goss PE, Ingle JN, Margino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG Ma.17. J Natl Cancer Inst 2005; 97: 1262-1271.
11. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
12. https://www.adjuvantonline.com/breast.jsp.
13. NCCN Clinical Practice Guidelines in Oncology Breast Cancer. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
15. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
16. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
17. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (Suppl 1): S3-S18.
18. Hershman DL, McMahon DJ, Crew KD et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739-4745.